Ventricular fibrillation (VF) is a cause of death in bupivacaine-induced cardiovascular toxicity. We have examined the therapeutic effects of lidocaine on the threshold for bupivacaine-induced VF in in situ beating swine hearts. Twenty-four animals were allocated to one of three groups: 0.25% bupivacaine, 1% lidocaine or 0.25% bupivacaine with 1% lidocaine were infused into the left anterior descending coronary artery in increasing doses of 0, 1, 2, 4, 8 and 16 ml h 91 for 15 min, respectively. ECG and haemodynamic variables were monitored continuously during infusion. Regional myocardial function in the area supplied by the left anterior descending coronary artery was assessed using the sonomicrometry technique. VF did not occur in the lidocaine group. VF developed at higher infusion rates in animals given bupivacaine with lidocaine (in one animal at an infusion rate of 8 ml h ). This study indicates that a combination of lidocaine and bupivacaine increased the threshold for bupivacaine-induced VF without further depressing myocardial contractility. (Br.
Bupivacaine-induced cardiotoxicity is characterized by depression of myocardial conductance and contraction. While recent reports, [1] [2] [3] including one from our laboratory, have demonstrated that amrinone reverses depressed myocardial contractility, there is no accepted therapy to correct conduction abnormality. Correction or avoidance of conduction abnormality is important because tachyarrhythmias and ventricular fibrillation (VF) caused by bupivacaine-induced cardiotoxicity may be fatal. 4 The mechanism of myocardial conduction abnormality has been explained by the receptor modulated theory. 5 Bupivacaine leads to enhanced myocardial sodium channel block during a cardiac cycle because it dissociates slowly during diastole (fast in, slow out), unlike lidocaine which dissociates from the myocardial sodium channels swiftly during diastole (fast in, fast out). The modulated receptor hypothesis has been extended for a mixture of local anaesthetics which compete for the same binding site of the sodium channel. 6 In an in vitro study using guinea pig ventricular myocardium, it has been shown that a drug with rapid binding and unbinding kinetics, such as lidocaine, displaces a drug with slower binding kinetics, such as bupivacaine, resulting in less sodium channel block with the combination of the two drugs than that produced by bupivacaine alone. However, the beneficial effects of lidocaine on bupivacaineinduced cardiotoxicity have not been demonstrated in vivo.
We hypothesized that, if the theory is true, in vivo the combination of lidocaine and bupivacaine should result in a higher VF threshold than that with bupivacaine alone. As there is a possibility that myocardial contractility might be depressed further by such a combination than by bupivacaine alone, 7 this combination should be examined before clinical use of lidocaine in bupivacaine-induced cardiotoxicity. Therefore, we examined the hypothesis and the effects on myocardial contractility in vivo using an animal model similar to that used in our laboratory. 3 8 
Materials and methods
The study was approved by the Animal Research Committee of Kawasaki Medical School (No. 95-048). Twenty-four pigs, weighing 25-43 kg, were anaesthetized with pentobarbital 600 mg i.v. after administration of ketamine 500 mg i.m. The trachea was intubated and the lungs ventilated with a tidal volume adjusted to maintain normocapnia (4.7-5.3 kPa) and a ventilatory frequency of 15 bpm. Anaesthesia was maintained with 50% nitrous oxide and 2-3% sevoflurane during surgical preparation. After instrumentation, sevoflurane was discontinued, and fentanyl was infused at a rate of 0.5 mg h 91 to the end of the experiment. Neuromuscular block was maintained with pancuronium 4 mg h 91 throughout the study. Rectal temperature was maintained at approximately 37-38 ЊC by a water blanket.
SURGICAL PREPARATION
The right carotid artery and right external jugular vein were cannulated. Ringer's lactate solution was infused at a rate of 10 ml kg 91 h 91 during surgical preparation and at a rate of 5 ml kg 91 h 91 via a venous catheter after surgical preparation. After median sternotomy, a 14-mm ultrasonic transit-time flow probe was placed around the root of the ascending aorta for measurement of cardiac output (CO) via a flowmeter (T208; Transonic Systems Inc., New York, NY, USA). Animals were then turned from the supine to the right lateral position. Left thoracotomy and pericardiotomy were performed through the fifth intercostal space, and the heart was placed in a pericardial cradle. The left anterior descending coronary artery (LAD) was dissected free, proximal to the first diagonal branch, to measure its blood flow (Q LAD ) using an ultrasonic flow probe (2 mm in diameter). The value was corrected for myocardial weight. Then a 22-gauge catheter was inserted into the LAD via a puncture and advanced 0.5-1.0 cm in the retrograde direction for infusion of local anaesthetics. Another catheter was placed in the anterior interventricular vein for blood sampling. A pre-calibrated micromanometer catheter (7.5 Fr. Goodtec, Huntington Beach, CA, USA) was inserted into the left ventricle to measure left ventricular pressure through the apex of the heart. Regional myocardial function was evaluated by the sonomicrometry technique, as described previously. 8 A pair of ultrasonic dimension crystals were placed in an equatorial plane into the subendocardium supplied by the LAD for measurement of segmental length. The signals of ventricular pressure and sonomicrometry were digitized at 250 Hz via a computer interface with a 12-bit analogueto-digital converter and stored for subsequent analysis. The percent systolic segment shortening (SS) was calculated off-line from the following formula: SS : (EDL -ESL) EDL for 15 min into the LAD with a syringe pump (STC-521, Terumo, Tokyo, Japan) via the catheter in animals of the corresponding groups. When VF occurred, resuscitation was not attempted and the experiment was terminated. Haemodynamic measurements and blood sampling were carried out after at least 10 min of each infusion rate. Blood samples obtained from the interventricular vein were used for measurement of plasma concentrations of lidocaine and bupivacaine using a fluorescence polarization immunoassay and high-pressure liquid chromatography, respectively.
DATA ANALYSIS
Data are expressed as mean (SEM). Statistical analysis of data during baseline (0 ml h 91 infusion rate) and during infusion of local anaesthetics into the LAD was performed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference test. Pairwise comparisons on the corresponding steps were performed by Student's t test with Bonferroni's correction. The inhibitory infusion rates of local anaesthetics for 50% SS (IR 50 ) were calculated from dose-response curves of normalized SS vs infusion rate. The Mann-Whitney U test was used to compare the distribution of VF at different infusion rates. P:0.05 was considered statistically significant. Haemodynamic data during intracoronary infusion of local anaesthetics are presented in table 4. There were no significant differences in haemodynamic variables such as HR, MAP, CO and Q LAD between the three groups. Although these variables did not change from baseline during stepwise Figure 2 Normalized systolic segment shortening (SS) of the LAD region during intracoronary infusion of local anaesthetics (1% lidocaine, 0.25% bupivacaine or 1% lidocaine with 0.25% bupivacaine). SS decreased in a dose-dependent manner in the three groups. The infusion rate for 50% inhibition of SS (IR 50 ) was significantly greater during infusion of lidocaine (5.83 (0.87) ml h 91 ) than during infusion of bupivacaine or bupivacaine with lidocaine (2.43 (0.43), 3.54 (0.56) ml h 91 , respectively). 
Discussion
As the anaesthetic potency of 0.25% bupivacaine is the same as that of 1% lidocaine, a 1% lidocaine with 0.25% bupivacaine solution is twice as potent as a 0.25% bupivacaine solution. Nevertheless, higher infusion rates of the bupivacaine with lidocaine solution were needed for induction of VF compared with those of the bupivacaine solution. Furthermore, the QRS interval in group Bup was widened at an infusion rate of 4 ml h 91 compared with baseline values, whereas that of group Bup;Lid did not differ between baseline and an infusion rate of 4 ml h 91 . These in vivo findings indicate that the threshold for bupivacaine-induced VF was increased and conduction abnormality attenuated in the presence of lidocaine. Therefore, we have confirmed the extended modulated receptor hypothesis in vivo. It is speculated therefore that in the event of accidental intravascular injection during regional anaesthesia, the use of a mixture of lidocaine and bupivacaine would result in less conduction abnormality and less chance of VF than would occur with a bupivacaine solution.
However, we did not find any direct evidence to support treatment against bupivacaine-induced cardiotoxicity with lidocaine, because a mixture of bupivacaine and lidocaine was used in this study. Interestingly, it has been reported that lidocaine was effective in conduction abnormality induced by propoxyphene, the major metabolite of which has slow unbinding kinetics with myocardial sodium channels. 9 The accompanying experiment using rabbit atrial myocytes demonstrated that the recovery time for sodium channel block was shortened from 14.3 (2.9) s during exposure to propoxyphene alone to 1.6 (0.9) s during exposure to a lidocaine and propoxyphene mixture. de Jong and Davis 10 reported that lidocaine converted refractory arrhythmias after bupivacaine overdose in cats undergoing ventilation. Based on these reports, we believe that sodium channel block is attenuated, even if lidocaine is administered by the same mechanism, during bupivacaineinduced cardiotoxicity. However, it must be noted that administration of lidocaine has a limitation, because VF occurred in group Bup;Lid at higher infusion rates. Therefore, further studies are necessary to define the limit of lidocaine treatment against bupivacaine-induced cardiotoxicity.
According to the modulated receptor hypothesis, shortening of action potential duration, decreasing heart rate and induction of diastolic hyperpolarization during diastole are thought to effectively minimize accumulation of sodium channel block with bupivacaine. 5 In fact, potassium channel openers have been shown to attenuate atrioventricular block produced by bupivacaine in isolated guinea pig hearts, presumably by shortening of action potential duration and hyperpolarization. 11 These measures are, however, not feasible during routine clinical practice because of their myocardial depressant effects.
Although many drugs, such as magnesium, 12 clonidine, 13 and hexamethonium, 14 have been reported to have a beneficial effect on bupivacaineinduced arrhythmias in experimental studies, their mechanisms have remained speculative. More importantly, these drugs have not been reported to be clinically effective. Epinephrine is often added to local anaesthetics to prevent rapid vascular absorption and to prolong duration of block. It does not, however, protect against bupivacaine-induced cardiotoxicity 15 or even potentiate toxicity. 16 This is explained in part by its arrhythmogenic property. Kasten and Martin 17 showed that bretylium, which is an antifibrillatory agent, but not lidocaine, effectively corrected bupivacaine-induced cardiotoxicity. The discrepancy between their results and ours may be explained by the difference in the experimental model. They examined the effect on ventricular tachycardia threshold using burst ventricular pacing instead of the occurrence of actual VF. Moreover, as bretylium prolongs ventricular action potential duration and increases heart rate because of release of catecholamines, it may enhance bupivacaine-induced sodium channel block and therefore worsen cardiotoxicity.
Even at the highest infusion rate, lidocaine did not cause QRS widening. Moreover, no animal in group Lid died of VF despite a high mean venous plasma concentration of 58.3 (6.7) g ml
91
. This may suggest a greater margin of safety against VF during lidocaine-induced cardiotoxicity. This is consistent with previous reports in sheep by Nancarrow and colleagues. 18 They reported that respiratory depression and hypotension were the causes of death in lidocaine-treated sheep, whereas three of four bupivacaine-treated sheep died after sudden onset of VF or ventricular tachycardia.
The dose-response relationship for SS revealed no difference between groups Bup and Bup;Lid, although SS decreased with increase in infusion rate of local anaesthetics in the three groups. This indicates that inclusion of lidocaine at the same potency did not increase bupivacaine-induced depression of myocardial contractility. In support of these findings, de Jong and Davis showed that hypotension was not precipitated by lidocaine in cats after bupivacaine-induced cardiotoxicity. 10 There were also no significant differences in Q LAD , HR, MAP or CO between groups Bup;Lid and Bup. We conclude that the combined use of lidocaine and bupivacaine is not associated with further depression of myocardial contractility.
We used the selective LAD infusion technique in beating hearts in this study. An advantage of our model was that we could evaluate the direct myocardial effects of drugs without interference of other organs. This is important because bupivacaineinduced cardiotoxicity is enhanced by hypoxia and acidosis 19 caused by convulsion or respiratory depression. However, we admit that this model is affected by the re-entry phenomenon in contrast with the clinical situation where the entire heart is exposed to drugs. This may explain why VF occurred without any arrhythmias in this study except for one case of bigeminy, although it is reported that arrhythmias often precede VF during cardiotoxicity induced with i.v. bupivacaine infusion. 20 It is notable that mean body weight in group Bup was significantly less than those of the other groups. However, we do not believe that this difference affected the results, because plasma concentrations of bupivacaine and lidocaine in the anterior intraventricular vein were similar in groups Bup and Bup;Lid groups and in groups Lid and Bup;Lid at corresponding infusion rates.
In summary, the results of this study demonstrated that lidocaine increased the threshold of bupivacaine-induced VF without enhancing myocardial depression. We therefore recommend that regional anaesthesia with relatively high doses of local anaesthetics be performed with a mixture including lidocaine rather than with bupivacaine alone. Furthermore, the results of this study suggest that lidocaine might be the drug of choice for bupivacaine-induced cardiotoxicity predisposing to VF.
